Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 7/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | IDO1 | P14902 | 2/20 | 0.54 |
| ▸ | AGXT | P21549 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 3/20 | 0.50 |
| ▸ | PNMT | P11086 | 2/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | RXRB | P28702 | 1/20 | 0.42 |
| ▸ | RXRG | P48443 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7968356 | 1.00 | TACR1 (0.65) | TACR1CYP3A4IDO1AGXTMAOB | |
| SCHEMBL4986022 | 0.83 | TACR1 (0.77) | TACR1CYP3A4IDO1AGXT | |
| SCHEMBL8857374 | 0.83 | TACR1 (0.56) | TACR1CYP3A4IDO1AGXTMAOB | |
| SCHEMBL7967707 | 0.81 | TACR1 (0.59) | TACR1IDO1AGXT | |
| SCHEMBL2781643 | 0.81 | TACR1 (0.59) | TACR1IDO1AGXT | |
| SCHEMBL7965700 | 0.81 | TACR1 (0.59) | TACR1IDO1AGXT | |
| SCHEMBL7965713 | 0.81 | IDO1 (0.54) | TACR1IDO1AGXTMAOBTAAR1 | |
| SCHEMBL7965716 | 0.81 | IDO1 (0.54) | TACR1IDO1AGXTMAOBTAAR1 | |
| SCHEMBL25185775 | 0.80 | TACR1 (0.60) | TACR1CYP3A4IDO1AGXTPNMT | |
| SCHEMBL25185774 | 0.80 | TACR1 (0.60) | TACR1CYP3A4IDO1AGXTPNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6274715-B1 | SEMISYNTHETIC MACROLIDES, USEFUL IN BACTERIAL INFECTIONS TREATMENT AND PREVENTION, HAS LESS POTENTIAL FOR DEVELOPING RESISTANCE, IMPROVED OR MODIFIED PROFILES OF DESIRED GRAM-NEGATIVE ACTIVITY | ABBOTT LABORATORIES | 2001-08-14 | — | — | US | disclosed |
| EP-0961776-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | Abbott Laboratories (US) | 1999-12-08 | — | — | EP | disclosed |
| WO-1998030574-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1998-07-16 | — | — | WO | disclosed |